2Seventy Bio

2Seventy Bio Dividend Yield

Delisted

Dividend Yield of 2Seventy Bio (TSVT) as of Oct 17, 2026.

Dividend Yield

-

Last updated:

Dividend Yield of 2Seventy Bio is 2026 - . Dividend Yield of 2Seventy Bio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2Seventy Bio Inc, headquartered in Cambridge, Massachusetts, is a biotechnology company specializing in cell and gene therapies. The company, listed on October 18, 2021, employs 854 full-time staff and focuses on developing targeted therapies for cancer patients using T cell engineering and lentiviral vector technologies. Its clinical programs include SC-DARIC33 for pediatric AML and bbT369 for B-cell non-Hodgkin lymphoma, alongside preclinical initiatives like bbT4015. Collaborations with Bristol Myers Squibb support the delivery of Abecma for multiple myeloma treatment in the U.S. 2Seventy Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2Seventy Bio stock

On Eulerpool you can find the complete historical development of Dividend Yield 2Seventy Bio since 2006 – with annual values, charts, and detailed analysis.

Dividend yield measures the annual dividend payment relative to the stock price. It shows the return an investor receives from dividends alone.

Dividend Yield's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Yield's 2Seventy Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — 2Seventy Bio

All Key Metrics — 2Seventy Bio